He rose through the ranks to become President & CEO where he grew the company until it was acquired by PPG Industries in 1999. Ted started his career at Products Research & Chemical Corporation, a global leader in aircraft sealants and coatings. Fuller from five business units to three global business units. He led the integration of Royal and the reorganization of H.B. Fuller (NYSE: FUL) in 2017 where he joined as EVP and Chief Operating Officer. After partnering with Arsenal Capital and American Securities as part of two subsequent recapitalizations, Ted led the sale of Royal to H.B.
#Georgia retina buyout series#
Ted founded Royal Adhesives & Sealants in partnership with Quad-C Management in 2003 and grew the business through a series of 19 acquisitions into one of the top 10 adhesives and sealant companies in the world. He is a seasoned M&A deal leader, operating executive, entrepreneur, and investor with over 40 years’ experience in the specialty chemicals industry. degree in Finance and Accounting from Ithaca College. He also previously held investment banking roles at Merrill Lynch in M&A and Bank of America in Leveraged Finance.
#Georgia retina buyout professional#
Prior to joining NuSil, Scott was an investment professional at Quad-C and Apax Partners, where he evaluated and executed private equity investments in various industries.
He has sourced and executed several private transactions in the specialty industrials sector, including New Mountain Capital’s acquisition of Gelest in 2017 and Quad-C’s acquisition of Boulder Scientific Company in 2019. He previously was an executive advisor to New Mountain Capital and a member of Quad-C’s executive advisory board. Scott currently serves on the boards of Boulder Scientific Company, Emergence Health and Versant Diagnostics. During his tenure as President of NuSil, Scott led the team that diversified the company into new market segments including electronics, personal care and drug-delivery and grew internationally by expanding in Europe and building a business in Asia. Prior to founding Iron Path, he was an executive at NuSil Technology, a global leader in specialty materials for healthcare and aerospace applications. Scott co-founded Iron Path Capital in 2021, co-leads the firm’s private equity execution and leads Iron Path’s “Full Immersion” program. degree in Finance & Accounting from Ithaca College and an M.B.A. Morgan Chase in the Leveraged Finance Group where he focused on providing senior and subordinated debt financing for a broad range of leveraged buyout transactions.
Prior to joining Quad-C, he worked at JLL Partners where he evaluated and executed private equity investments in various industries. His investment experience at Quad-C includes companies such as Boulder Scientific Company, Prism Vision Group, Retina Group of Washington, VMG Health, Compassion First, Dental Care Alliance, Towncare Dental, NuSil Technology and Royal Adhesives & Sealants. Rob currently serves on the boards of Emergence Health and Versant Diagnostics. Rob was one of two senior professionals that established the healthcare vertical at Quad-C and he also led the specialty chemicals initiative for seven years. Prior to founding Iron Path, he was a Principal with Quad-C where he spent nearly 14 years on deal teams that invested over $750 million of equity. Rob co-founded Iron Path Capital in 2021, co-leads the firm’s private equity execution and leads Iron Path’s internal operations.
0 kommentar(er)
